Skip to content

Label change record

Every change to the wording this site quotes from the FDA labels for eight GLP-1 medicines since January 2024: where and how to inject, the dose schedule, dose increases, missed doses and storage out of the fridge. Across 72 label versions, 38 changed that wording. Each change below is quoted word for word from the archived label on DailyMed.

How it is made: every version of each label is downloaded from DailyMed's archive and compared with the version before it. Only sentences on those topics are compared, and wording that differs only in spacing, punctuation or section numbers is treated as unchanged. Under each changed sentence is its topic and, where the per-pen card quotes lines on that topic, which card lines it touches. It reports what the label text says; it does not interpret it. Last refreshed October 6, 2026. The full record is published as data for anyone to check or cite.

Ozempic (semaglutide)

6 label versions since January 2024; 4 changed the wording this site quotes, most recently May 19, 2026.

What the current label says

The per-pen card's lines

  • Device (two card lines): changed in one version, most recently May 19, 2026.
  • Dose schedule (three card lines): changed in four versions, most recently May 19, 2026.
  • Dose increase (four card lines): changed in three versions, most recently May 19, 2026.
  • Missed dose (one card line): no change in this period.
  • Storage out of fridge (five card lines): changed in two versions, most recently May 19, 2026.
  • May 19, 2026 (label version 19, published on DailyMed May 21, 2026; this version)

    No longer in the label

    • “After first use of the OZEMPIC pen, the pen can be stored for 56 days at controlled room temperature 59°F to 86°F (15°C to 30°C) or in a refrigerator 36°F to 46°F (2°C to 8°C).”storage out of fridge · touches the five card lines on storage out of fridge
    • “Injection: 2 mg/3 mL (0.68 mg/mL) available in:”device · touches the two card lines on device
    • “Injection: 4 mg/3 mL (1.34 mg/mL) available in:”device · touches the two card lines on device
    • “Injection: 8 mg/3 mL (2.68 mg/mL) available in:”device · touches the two card lines on device
    • “Prior to first use, OZEMPIC should be stored in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC).”storage out of fridge · touches the five card lines on storage out of fridge
    • “The 2 mg/1.5 mL (1.34 mg/mL) strength is not currently marketed by Novo Nordisk Inc.”device · touches the two card lines on device
    • “Treatment with OZEMPIC 1 mg once weekly for 56 weeks resulted in a statistically significant reduction in HbA 1c compared to exenatide 2 mg once weekly (see Table 5 ).”dose schedule · touches the three card lines on dose schedule

    New in the label

    • “After first use of the OZEMPIC pen, the pen can be stored for 56 days at controlled room temperature 15°C to 30°C (59°F to 86°F) or in a refrigerator 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the five card lines on storage out of fridge
    • “Choose Your Injection Site”injection site
    • “Clean the injection site with an alcohol wipe and allow to dry.”injection site
    • “If blood appears at the injection site, lightly press with a cotton ball or gauze over it, without rubbing.”injection site
    • “If needed, the prefilled syringes can be stored out of the refrigerator between 46°F to 86°F (8°C to 30°C) for up to 28 days.”storage out of fridge · touches the five card lines on storage out of fridge · the card quotes these words today
    • “Injection: 0.25 mg, 0.5 mg or 1 mg per 0.5 mL in a single-dose prefilled syringe ( 3 )”device · touches the two card lines on device · the card quotes these words today
    • “Injection: 2 mg/3 mL (0.68 mg/mL) for 4 doses of 0.25 mg and 2 doses of 0.5 mg or 4 doses of 0.5 mg, 4 mg/3 mL (1.34 mg/mL) for 4 doses of 1 mg, and 8 mg/3 mL (2.68 mg/mL) for 4 doses of 2 mg in single-patient-use pens ( 3 )”device · touches the two card lines on device · the card quotes these words today
    • “Pinch and hold a fold of skin at the injection site between your thumb and fingers.”injection site
    • “Population PK model also included maintenance dose and injection site as covariates.”dose increase · touches the four card lines on dose increase
    • “Prior to first use, the OZEMPIC pen should be stored in a refrigerator between 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the five card lines on storage out of fridge
    • “Record the date your prefilled syringe was removed from the refrigerator and dispose of it, if not used within 28 days.”storage out of fridge · touches the five card lines on storage out of fridge · the card quotes these words today
    • “Store the OZEMPIC prefilled syringe refrigerated at 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the five card lines on storage out of fridge
    • “Store the unused OZEMPIC prefilled syringes in the refrigerator between 36°F to 46°F (2°C to 8°C).”storage out of fridge · touches the five card lines on storage out of fridge · the card quotes these words today
    • “Your healthcare provider can help you choose the injection site that is best for you.”injection site
  • October 14, 2025 (label version 18, published on DailyMed Jan 26, 2026; this version)

    No longer in the label

    • “In each case, inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration (”dose schedule · touches the three card lines on dose schedule
    • “In each case, patients can then resume their regular once weekly dosing schedule.”dose schedule · touches the three card lines on dose schedule
    • “In patients with type 2 diabetes, the mean population-PK estimated steady-state concentrations following once weekly subcutaneous administration of 0.5 mg and 1 mg semaglutide were approximately 65 ng/mL and 123 ng/mL, respectively.”dose schedule · touches the three card lines on dose schedule

    New in the label

    • “Treatment with OZEMPIC 1 mg once weekly for 56 weeks resulted in a statistically significant reduction in HbA 1c compared to exenatide 2 mg once weekly (see Table 5 ).”dose schedule · touches the three card lines on dose schedule
    • “Treatment with OZEMPIC 2 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA 1c compared with OZEMPIC 1 mg (see Table”dose schedule · touches the three card lines on dose schedule
  • October 14, 2025 (label version 17, published on DailyMed Nov 17, 2025; this version)

    No longer in the label

    • “To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dosage ( 1 , 2.2 ).”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase

    New in the label

    • “To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dosage.”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase
  • January 2, 2025 (label version 16, published on DailyMed Feb 10, 2025; this version)

    No longer in the label

    • “If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dosage, the dosage may be increased to 1 mg once weekly.”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase
    • “If additional glycemic control is needed after at least 4 weeks on the 1 mg dosage, the dosage may be increased to 2 mg once weekly.”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase
    • “In each case, inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration ( 2.2 )] .”dose schedule · touches the three card lines on dose schedule
    • “In patients with type 2 diabetes, the mean population-PK estimated steady-state concentrations following once weekly subcutaneous administration of 0.5 mg and 1 mg semaglutide were approximately 65.0 ng/mL and 123.0 ng/mL, respectively.”dose schedule · touches the three card lines on dose schedule
    • “Inject OZEMPIC subcutaneously to the abdomen, thigh, or upper arm.”injection site
    • “Prior to first use, OZEMPIC should be stored in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC) (Table 10).”storage out of fridge · touches the five card lines on storage out of fridge
    • “Treatment with OZEMPIC 0.5 mg and 1 mg once weekly for 56 weeks resulted in a statistically significant reduction in HbA 1c compared to sitagliptin (see Table 4 and Figure 5).”dose schedule · touches the three card lines on dose schedule
    • “Treatment with OZEMPIC 1 mg once weekly for 56 weeks resulted in a statistically significant reduction in HbA 1c compared to exenatide 2 mg once weekly (see Table 5).”dose schedule · touches the three card lines on dose schedule
    • “Treatment with OZEMPIC 2 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA 1c compared with OZEMPIC 1 mg (see Table 7).”dose schedule · touches the three card lines on dose schedule

    New in the label

    • “0.5 mg dosage, the dosage may be increased to 1 mg once weekly.”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase
    • “1 mg dosage, the dosage may be increased to 2 mg once weekly.”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase
    • “Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.7 ), Adverse Reactions ( 6.1 )].”dose increase · touches the four card lines on dose increase
    • “In each case, inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration (”dose schedule · touches the three card lines on dose schedule
    • “In patients with type 2 diabetes, the mean population-PK estimated steady-state concentrations following once weekly subcutaneous administration of 0.5 mg and 1 mg semaglutide were approximately 65 ng/mL and 123 ng/mL, respectively.”dose schedule · touches the three card lines on dose schedule
    • “Increase the dosage to the maintenance dosage, 1 mg once weekly, after at least 4 weeks on the 0.5 mg dosage.”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase
    • “Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm.”injection site
    • “Prior to first use, OZEMPIC should be stored in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC).”storage out of fridge · touches the five card lines on storage out of fridge
    • “Recommended Maintenance Dosage in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease”dose increase · touches the four card lines on dose increase
    • “Recommended Maintenance and Maximum Dosages for Glycemic Control”dose increase · touches the four card lines on dose increase
    • “The recommended maintenance dosage is 0.5 mg, 1 mg, or 2 mg, injected subcutaneously once weekly, based on glycemic control.”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase · the card quotes these words today
    • “To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dosage ( 1 , 2.2 ).”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase

Wegovy (semaglutide)

13 label versions since January 2024; 8 changed the wording this site quotes, most recently June 18, 2026.

What the current label says

The per-pen card's lines

  • Device (four card lines): changed in three versions, most recently June 18, 2026.
  • Dose schedule (three card lines): changed in eight versions, most recently June 18, 2026.
  • Dose increase (seven card lines): changed in six versions, most recently June 18, 2026.
  • Missed dose (two card lines): changed in six versions, most recently June 18, 2026.
  • Storage out of fridge (six card lines): changed in four versions, most recently June 18, 2026.
  • June 18, 2026 (label version 19, published on DailyMed Jun 30, 2026; this version)

    No longer in the label

    • “Do not store WEGOVY injection in the freezer or directly adjacent to the refrigerator cooling element.”storage out of fridge · touches the six card lines on storage out of fridge
    • “If 2 or more consecutive doses of WEGOVY injection are missed, resume dosing as scheduled or, if needed, reinitiate WEGOVY injection and follow the dosage escalation schedule, which may reduce the occurrence of gastrointestinal adverse reactions associated with reinitiation of treatment [see Dosage and Administration ( 2.2 )].”dose increase, missed dose · touches the 9 card lines on dose increase and missed dose
    • “If you miss a dose of WEGOVY and the next schedule dose is less than 2 days away (48 hours), do not administer the dose.”missed dose · touches the two card lines on missed dose
    • “If you miss doses of WEGOVY for 2 or more weeks, take your next dose on the regularly scheduled day or call your healthcare provider to talk about how to restart your treatment.”missed dose · touches the two card lines on missed dose
    • “The maintenance dosage of WEGOVY injection for weight reduction in pediatric patients aged 12 years and older is either 2.4 mg (recommended), 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “Throw away the pen if WEGOVY has been frozen, has been exposed to light or temperatures above 86°F (30°C), has been out of the refrigerator for 28 days or longer, or after use.”storage out of fridge · touches the six card lines on storage out of fridge

    New in the label

    • “0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL, or 7.2 mg/0.75 mL (WEGOVY HD) in a single-dose pen”device · touches the four card lines on device · the card quotes these words today
    • “0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, or 2.4 mg/0.75 mL in a single-dose syringe”device · touches the four card lines on device · the card quotes these words today
    • “9.6 mg/3 mL (3.2 mg/mL)”device · touches the four card lines on device
    • “9.6 mg/3 mL (3.2 mg/mL) solution in a single-patient-use pen (WEGOVY FlexTouch) that delivers four 2.4 mg/0.75 mL doses”device · touches the four card lines on device · the card quotes these words today
    • “After first use, WEGOVY FlexTouch single-patient-use pen can be stored for 56 days between 15°C to 30°C (59°F to 86°F) or in a refrigerator 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the six card lines on storage out of fridge
    • “After first use, store WEGOVY FlexTouch between 68°F to 77°F (20°C to 25°C) or in a refrigerator 36°F to 46°F (2°C to 8°C) for up to 56 days.”storage out of fridge · touches the six card lines on storage out of fridge · the card quotes these words today
    • “After first use, store WEGOVY FlexTouch pen between 59°F to 86°F (15°C to 30°C) or in the refrigerator between 36°F to 46°F (2°C to 8°C) for up to 56 days.”storage out of fridge · touches the six card lines on storage out of fridge · the card quotes these words today
    • “Choose an injection site on your upper arms, stomach or upper legs.”injection site
    • “Do not store WEGOVY in the freezer or directly adjacent to the refrigerator cooling element.”storage out of fridge · touches the six card lines on storage out of fridge
    • “If 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions [see Dosage and Administration ( 2.2 ), Warnings and Precautions (”dose increase, missed dose · touches the 9 card lines on dose increase and missed dose
    • “If blood appears at the injection site, press the site lightly with a cotton ball or gauze.”injection site
    • “If you miss a dose of WEGOVY and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose.”missed dose · touches the two card lines on missed dose · the card quotes these words today
    • “If you miss doses of WEGOVY for 2 or more consecutive weeks, contact your healthcare provider to talk about how to restart your treatment.”missed dose · touches the two card lines on missed dose · the card quotes these words today
    • “Let the injection site dry before you inject your dose.”injection site
    • “Prior to first use, store WEGOVY FlexTouch single-patient-use pen in a refrigerator between 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the six card lines on storage out of fridge
    • “Store in the refrigerator between 36°F to 46°F (2°C to 8°C).”storage out of fridge · touches the six card lines on storage out of fridge
    • “The maintenance dosage of WEGOVY injection for weight reduction in pediatric patients aged 12 years and older is either 2.4 mg (recommended), or 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase · the card quotes these words today
    • “Throw away if the WEGOVY FlexTouch pen if it has been frozen, has been exposed to light or temperatures above 86°F (30°C), or has been out of the refrigerator for 56 days or longer.”storage out of fridge · touches the six card lines on storage out of fridge
    • “Throw away if the single-patient-use WEGOVY FlexTouch pen has been frozen, has been exposed to light or temperatures above 86°F (30°C), or has been out of the refrigerator for 56 days or longer.”storage out of fridge · touches the six card lines on storage out of fridge
    • “Throw away the WEGOVY single-dose pen or syringe if it has been frozen, has been exposed to light or temperatures above 86°F (30°C), has been out of the refrigerator for 28 days or longer, or after use.”storage out of fridge · touches the six card lines on storage out of fridge · the card quotes these words today
    • “Use Wegovy FlexTouch Once Weekly”dose schedule · touches the three card lines on dose schedule
    • “You may inject in the same body area each week, but make sure it is not in the same spot used for the last injection.”injection site
  • May 5, 2026 (label version 18, published on DailyMed May 22, 2026; this version)

    No longer in the label

    • “7.2 mg/0.75 mL (WEGOVY HD)”device · touches the four card lines on device
    • “Do not store WEGOVY in the freezer or directly adjacent to the refrigerator cooling element.”storage out of fridge · touches the six card lines on storage out of fridge
    • “Store the WEGOVY single-dose pen in the refrigerator from 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the six card lines on storage out of fridge
    • “WEGOVY Injection (2.4 mg once weekly)”dose schedule · touches the three card lines on dose schedule

    New in the label

    • “(2.4 mg Once Weekly)”dose schedule · touches the three card lines on dose schedule
    • “Clean the injection site with an alcohol wipe and allow to dry.”injection site
    • “Do not store WEGOVY injection in the freezer or directly adjacent to the refrigerator cooling element.”storage out of fridge · touches the six card lines on storage out of fridge
    • “If blood appears at the injection site, lightly press with a cotton ball or gauze over it, without rubbing.”injection site
    • “If needed, the prefilled syringes can be stored out of the refrigerator between 46°F to 86°F (8°C to 30°C) for up to 28 days.”storage out of fridge · touches the six card lines on storage out of fridge
    • “Once Daily Tablet Dosage”dose schedule · touches the three card lines on dose schedule
    • “Pinch and hold a fold of skin at the injection site between your thumb and fingers.”injection site
    • “Record the date your prefilled syringe was removed from the refrigerator and dispose of it if not used within 28 days.”storage out of fridge · touches the six card lines on storage out of fridge
    • “Store the WEGOVY prefilled single-dose pen or single-dose syringe in the refrigerator from 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the six card lines on storage out of fridge
    • “Store the unused WEGOVY prefilled syringes in the refrigerator between 36°F to 46°F (2°C to 8°C).”storage out of fridge · touches the six card lines on storage out of fridge
  • March 19, 2026 (label version 17, published on DailyMed Apr 02, 2026; this version)

    No longer in the label

    • “Recommended Maintenance Dosage of WEGOVY Injection for Approved Indications”dose increase · touches the seven card lines on dose increase
    • “Store WEGOVY tablets at room temperature between 68°F and 77°F (20°C to 25°C).”storage out of fridge · touches the six card lines on storage out of fridge
    • “The maintenance dosage of WEGOVY injection for weight reduction in adults and pediatric patients aged 12 years and older is either 2.4 mg (recommended) or 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase

    New in the label

    • “7.2 mg/0.75 mL (WEGOVY HD)”device · touches the four card lines on device
    • “After dosage escalation, 1,149 patients received at least one dose of WEGOVY 7.2 mg injection, and 578 patients received 7.2 mg for at least 1 year.”dose increase · touches the seven card lines on dose increase
    • “Consider reescalation to 2.4 mg once weekly [see Adverse Reactions (”dose schedule · touches the three card lines on dose schedule
    • “Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (”dose increase · touches the seven card lines on dose increase
    • “Do not store WEGOVY in the freezer or directly adjacent to the refrigerator cooling element.”storage out of fridge · touches the six card lines on storage out of fridge
    • “Do not store WEGOVY in the freezer or directly beside the refrigerator cooling element.”storage out of fridge · touches the six card lines on storage out of fridge
    • “For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase · the card quotes these words today
    • “Of the patients who recovered after action taken with WEGOVY, 38 patients were re-escalated to 7.2 mg.”dose increase · touches the seven card lines on dose increase
    • “Recommended Maintenance Dosage of WEGOVY Injection for All Approved Indications”dose increase · touches the seven card lines on dose increase
    • “Store WEGOVY tablets at room temperature between 68°F to 77°F (20°C to 25°C).”storage out of fridge · touches the six card lines on storage out of fridge
    • “The average semaglutide steady state concentration following subcutaneous administration of WEGOVY 7.2 mg once weekly injection was approximately 230 nmol/L in patients with obesity (BMI greater than or equal to 30 kg/m 2 ).”dose schedule · touches the three card lines on dose schedule
    • “The maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase · the card quotes these words today
    • “The maintenance dosage of WEGOVY injection for weight reduction in pediatric patients aged 12 years and older is either 2.4 mg (recommended), 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “Throw away the pen if WEGOVY has been frozen, has been exposed to light or temperatures above 86°F (30°C), has been out of the refrigerator for 28 days or longer, or after use.”storage out of fridge · touches the six card lines on storage out of fridge
    • “Throw away the pen if WEGOVY has been frozen, has been exposed to light or temperatures above 86°F (30°C), or has been out of the refrigerator for 28 days or longer or after use.”storage out of fridge · touches the six card lines on storage out of fridge · the card quotes these words today
    • “WEGOVY Injection (2.4 mg once weekly)”dose schedule · touches the three card lines on dose schedule
    • “WEGOVY Injection (7.2 mg once weekly)”dose schedule · touches the three card lines on dose schedule
    • “to reduce excess body weight and maintain weight reduction long term with the 7.2 mg once weekly dosage.”dose schedule · touches the three card lines on dose schedule
  • December 22, 2025 (label version 14, published on DailyMed Jan 06, 2026; this version)

    No longer in the label

    • “2.2 Recommended Dosage Initiation and Escalation Schedule”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “2.3 Recommended Maintenance Dosage”dose increase · touches the seven card lines on dose increase
    • “2.4 Recommendations Regarding Missed Dose”missed dose · touches the two card lines on missed dose
    • “Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals.”dose schedule · touches the three card lines on dose schedule
    • “Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals.”dose schedule · touches the three card lines on dose schedule
    • “All patients received WEGOVY during the run-in period of 20 weeks that included 16 weeks of dose escalation.”dose increase · touches the seven card lines on dose increase
    • “Follow the recommended dosage initiation and escalation in Table 1 for all indications to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] .”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “For all other indications except for MASH treatment, the maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “For patients with MASH, the maintenance dosage of WEGOVY is 2.4 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “If 2 or more consecutive doses are missed, resume dosing as scheduled or, if needed, reinitiate WEGOVY and follow the dose escalation schedule, which may reduce the occurrence of gastrointestinal symptoms associated with reinitiation of treatment.”dose increase, missed dose · touches the 9 card lines on dose increase and missed dose
    • “If one dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible.”missed dose · touches the two card lines on missed dose
    • “If patients do not tolerate 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly.”dose schedule · touches the three card lines on dose schedule
    • “If you miss 1 dose of WEGOVY and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose.”missed dose · touches the two card lines on missed dose
    • “Inform patients if a dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible.”missed dose · touches the two card lines on missed dose
    • “Inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration ( 2.4 )] .”dose schedule · touches the three card lines on dose schedule
    • “Initiate WEGOVY with a dosage of 0.25 mg injected subcutaneously once weekly.”dose schedule · touches the three card lines on dose schedule
    • “Recommended Dosage Initiation and Escalation”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “Recommended Dosage Initiation and Escalation Schedule,”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “Recommended Maintenance Dosage ( 2.2 , 2.3 ) ………………….08/2025”dose increase · touches the seven card lines on dose increase
    • “See indication below (Subsection 2.3) for maintenance dosage”dose increase · touches the seven card lines on dose increase
    • “The maintenance dosage of WEGOVY for CV risk reduction and weight reduction is either 2.4 mg (recommended) or 1.7 mg injected subcutaneously once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The recommended dosage of WEGOVY in patients with hepatic impairment is the same as those with normal hepatic function.”dose schedule · touches the three card lines on dose schedule
    • “The recommended maintenance dosage of WEGOVY for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis is 2.4 mg injected subcutaneously once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The time of day and the injection site can be changed without dose adjustment.”injection site
    • “The use of WEGOVY (semaglutide 2.4 mg or 1.7 mg once weekly) in patients with type 1 diabetes mellitus or in combination with insulin has not been evaluated.”dose schedule · touches the three card lines on dose schedule
    • “Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage.”dose increase · touches the seven card lines on dose increase

    New in the label

    • “2.2 Recommended Dosage for WEGOVY Injection”dose schedule · touches the three card lines on dose schedule
    • “2.3 Recommended Dosage of WEGOVY Tablets”dose schedule · touches the three card lines on dose schedule
    • “2.4 Recommendations Regarding Missed Dose(s)”missed dose · touches the two card lines on missed dose
    • “Administer WEGOVY injection once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals.”dose schedule · touches the three card lines on dose schedule
    • “Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals.”dose schedule · touches the three card lines on dose schedule
    • “All patients received WEGOVY injection during the run-in period of 20 weeks that included 16 weeks of dose escalation.”dose increase · touches the seven card lines on dose increase
    • “Follow the dosage escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] .”dose increase · touches the seven card lines on dose increase
    • “Follow the dosage escalation in Table 2 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] .”dose increase · touches the seven card lines on dose increase
    • “If 2 or more consecutive doses of WEGOVY injection are missed, resume dosing as scheduled or, if needed, reinitiate WEGOVY injection and follow the dosage escalation schedule, which may reduce the occurrence of gastrointestinal adverse reactions associated with reinitiation of treatment [see Dosage and Administration ( 2.2 )].”dose increase, missed dose · touches the 9 card lines on dose increase and missed dose
    • “If a dose of WEGOVY tablets is missed, skip the missed dose and take the next dose the following day.”missed dose · touches the two card lines on missed dose
    • “If additional weight reduction is needed in patients with type 2 diabetes mellitus treated with WEGOVY 25 mg tablets, consider switching to WEGOVY 1.7 mg injection and follow the recommended dosage escalation for WEGOVY injection. [see Dosage and Administration ( 2.2 ), Use in Specific Populations ( 8.6 ), and Clinical Pharmacology ( 12.3 )].”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “If one dose of WEGOVY injection is missed and the next scheduled dose is:”missed dose · touches the two card lines on missed dose
    • “If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation.”dose increase · touches the seven card lines on dose increase · the card quotes these words today
    • “If patients do not tolerate the 25 mg once daily maintenance dosage, consider switching to WEGOVY injection 1.7 mg once weekly [see Dosage and Administration ( 2.5 )] .”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “If you miss a dose of WEGOVY and the next schedule dose is less than 2 days away (48 hours), do not administer the dose.”missed dose · touches the two card lines on missed dose
    • “If you miss a dose of WEGOVY, skip the missed dose and go back to your regular schedule for the next dose.”missed dose · touches the two card lines on missed dose
    • “In patients with type 2 diabetes, the average semaglutide blood concentrations following administration of WEGOVY 25 mg tablets once daily were lower than the average semaglutide blood concentrations following use of WEGOVY 2.4 mg injection once weekly [see Clinical Pharmacology ( 12.3 )] .”dose schedule · touches the three card lines on dose schedule
    • “In patients without type 2 diabetes, the average semaglutide blood concentrations following administration of WEGOVY 25 mg tablets once daily or WEGOVY 2.4 mg injection once weekly were similar.”dose schedule · touches the three card lines on dose schedule
    • “Inform patients if a dose of WEGOVY injection is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY injection as soon as possible.”missed dose · touches the two card lines on missed dose
    • “Inform patients if a dose of WEGOVY tablets is missed, skip the missed dose and take the next dose the following day [see Dosage and Administration ( 2.4 )] .”missed dose · touches the two card lines on missed dose
    • “Initiate WEGOVY tablet with a dosage of 1.5 mg once daily for 30 days.”dose schedule · touches the three card lines on dose schedule
    • “One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.”dose schedule · touches the three card lines on dose schedule
    • “Patients who could not tolerate the recommended escalation dosage, could stay at a lower dose level.”dose increase · touches the seven card lines on dose increase
    • “Recommended Dosage of WEGOVY Tablets for Cardiovascular Risk Reduction or Weight Reduction in Adults”dose schedule · touches the three card lines on dose schedule
    • “Recommended Maintenance Dosage of WEGOVY Injection for Approved Indications”dose increase · touches the seven card lines on dose increase
    • “Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase · the card quotes these words today
    • “Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications in Adults and Pediatric Patients Aged 12 Years and Older”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase · the card quotes these words today
    • “Refer to the full PI for maintenance dosages based on the indication.”dose increase · touches the seven card lines on dose increase
    • “See the indication below for the recommended maintenance dosage(s)”dose increase · touches the seven card lines on dose increase
    • “Store WEGOVY tablets at room temperature between 68°F and 77°F (20°C to 25°C).”storage out of fridge · touches the six card lines on storage out of fridge
    • “Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].”storage out of fridge · touches the six card lines on storage out of fridge
    • “Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces).”dose schedule · touches the three card lines on dose schedule
    • “The average semaglutide steady state concentration following subcutaneous administration of WEGOVY 2.4 mg once weekly was approximately 68 nmol/L in patients with type 2 diabetes and obesity or overweight (BMI greater than or equal to 27 kg/m 2 ).”dose schedule · touches the three card lines on dose schedule
    • “The average semaglutide steady state concentration following subcutaneous administration of WEGOVY 2.4 mg once weekly was approximately 75 nmol/L in patients with obesity or overweight (BMI greater than or equal to 27 kg/m 2 ).”dose schedule · touches the three card lines on dose schedule
    • “The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly.”dose schedule · touches the three card lines on dose schedule
    • “The maintenance dosage of WEGOVY injection for cardiovascular risk reduction in adults is either 2.4 mg (recommended) or 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase · the card quotes these words today
    • “The maintenance dosage of WEGOVY injection for weight reduction in adults and pediatric patients aged 12 years and older is either 2.4 mg (recommended) or 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The recommended maintenance dosage of WEGOVY injection for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults is 2.4 mg injected subcutaneously once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase · the card quotes these words today
    • “The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily for cardiovascular risk reduction and weight reduction in adults”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly.”dose schedule · touches the three card lines on dose schedule · the card quotes these words today
    • “The recommended starting dosage of WEGOVY tablets is 1.5 mg taken orally once daily.”dose schedule · touches the three card lines on dose schedule
    • “The steady-state concentrations increased approximately proportionally with doses up to 25 mg once daily.”dose schedule · touches the three card lines on dose schedule
    • “The time of day and the injection site can be changed without the need for a dosage modification.”injection site
    • “The usual recommended maintenance dosage of WEGOVY injection is 2.4 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “Then follow the dosage escalation schedule in Table 1, titrating every 4 weeks to achieve the maintenance dosage.”dose increase · touches the seven card lines on dose increase
    • “Then follow the dosage escalation schedule, titrating every 30 days to achieve the maintenance dosage.”dose increase · touches the seven card lines on dose increase
  • November 21, 2025 (label version 13, published on DailyMed Dec 05, 2025; this version)

    No longer in the label

    • “If you miss a dose of WEGOVY and the next schedule dose is less than 2 days away (48 hours), do not administer the dose.”missed dose · touches the two card lines on missed dose

    New in the label

    • “If patients do not tolerate 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly.”dose schedule · touches the three card lines on dose schedule
    • “If you miss 1 dose of WEGOVY and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose.”missed dose · touches the two card lines on missed dose
    • “Inform patients if a dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible.”missed dose · touches the two card lines on missed dose
    • “Inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration ( 2.4 )] .”dose schedule · touches the three card lines on dose schedule
    • “Initiate at 0.25 mg once weekly for 4 weeks.”dose schedule · touches the three card lines on dose schedule
    • “The use of WEGOVY (semaglutide 2.4 mg or 1.7 mg once weekly) in patients with type 1 diabetes mellitus or in combination with insulin has not been evaluated.”dose schedule · touches the three card lines on dose schedule
  • October 14, 2025 (label version 12, published on DailyMed Nov 17, 2025; this version)

    No longer in the label

    • “Consider reescalation to 2.4 mg once weekly [see Adverse Reactions (”dose schedule · touches the three card lines on dose schedule
    • “Dosage and Administration, Recommended Dosage Initiation and Escalation Schedule, Recommended Maintenance Dosage ( 2.2 , 2.3 )……………………… 08/2025”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “If patients do not tolerate 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly .”dose schedule · touches the three card lines on dose schedule
    • “If you miss 1 dose of WEGOVY and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose.”missed dose · touches the two card lines on missed dose
    • “Inform patients if a dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible.”missed dose · touches the two card lines on missed dose
    • “Inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration ( 2.4 )].”dose schedule · touches the three card lines on dose schedule
    • “Initiate at 0.25 mg once weekly for 4 weeks.”dose schedule · touches the three card lines on dose schedule
    • “Once Weekly Subcutaneous Dosage”dose schedule · touches the three card lines on dose schedule
    • “The use of WEGOVY (semaglutide 2.4 mg or 1.7 mg once weekly) in patients with type 1 diabetes mellitus or in combination with insulin has not been evaluated.”dose schedule · touches the three card lines on dose schedule

    New in the label

    • “If you miss a dose of WEGOVY and the next schedule dose is less than 2 days away (48 hours), do not administer the dose.”missed dose · touches the two card lines on missed dose
    • “Recommended Dosage Initiation and Escalation Schedule,”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “Recommended Maintenance Dosage ( 2.2 , 2.3 ) ………………….08/2025”dose increase · touches the seven card lines on dose increase
  • August 1, 2025 (label version 11, published on DailyMed Aug 29, 2025; this version)

    No longer in the label

    • “2.2 Recommended Dosage in Adults and Pediatric Patients Aged 12 Years and Older”dose schedule · touches the three card lines on dose schedule
    • “2.3 Recommendations Regarding Missed Dose”missed dose · touches the two card lines on missed dose
    • “Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (”dose increase · touches the seven card lines on dose increase
    • “Dosage Initiation and Escalation”dose increase · touches the seven card lines on dose increase
    • “Follow the dosage initiation and escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] .”dose increase · touches the seven card lines on dose increase
    • “If you miss a dose of WEGOVY and the next schedule dose is less than 2 days away (48 hours), do not administer the dose.”missed dose · touches the two card lines on missed dose
    • “Recommended Dosage Escalation in Adults and Pediatric Patients Aged 12 Years and Older”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly (2.2) .”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage (2.2 , 2.3).”dose increase · touches the seven card lines on dose increase

    New in the label

    • “2.2 Recommended Dosage Initiation and Escalation Schedule”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “2.3 Recommended Maintenance Dosage”dose increase · touches the seven card lines on dose increase
    • “2.4 Recommendations Regarding Missed Dose”missed dose · touches the two card lines on missed dose
    • “Consider reescalation to 2.4 mg once weekly [see Adverse Reactions (”dose schedule · touches the three card lines on dose schedule
    • “Dosage and Administration, Recommended Dosage Initiation and Escalation Schedule, Recommended Maintenance Dosage ( 2.2 , 2.3 )……………………… 08/2025”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “Dose escalation could be prolonged or patients could remain at a lower dose if 2.4 mg once weekly was not tolerable.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “Follow the recommended dosage initiation and escalation in Table 1 for all indications to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] .”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “For all other indications, except for MASH treatment, the maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “For patients with MASH, the maintenance dosage of WEGOVY is 2.4 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “If patients do not tolerate 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly .”dose schedule · touches the three card lines on dose schedule
    • “If patients do not tolerate the maintenance dosage of 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “If you miss 1 dose of WEGOVY and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose.”missed dose · touches the two card lines on missed dose
    • “Inform patients if a dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible.”missed dose · touches the two card lines on missed dose
    • “Inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration ( 2.4 )].”dose schedule · touches the three card lines on dose schedule
    • “Recommended Dosage Initiation and Escalation”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “See indication below (Subsection 2.3) for maintenance dosage”dose increase · touches the seven card lines on dose increase
    • “The maintenance dosage of WEGOVY for CV risk reduction and weight reduction is either 2.4 mg (recommended) or 1.7 mg injected subcutaneously once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The recommended maintenance dosage of WEGOVY for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis is 2.4 mg injected subcutaneously once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage ( 2.2 ).”dose increase · touches the seven card lines on dose increase
  • November 1, 2024 (label version 10, published on DailyMed Dec 12, 2024; this version)

    No longer in the label

    • “2.2 Recommended Dosage in Adults”dose schedule · touches the three card lines on dose schedule
    • “2.3 Recommended Dosage in Pediatric Patients Aged 12 Years and Older”dose schedule · touches the three card lines on dose schedule
    • “2.4 Recommendations Regarding Missed Dose”missed dose · touches the two card lines on missed dose
    • “If patients do not tolerate the 2.4 mg once-weekly maintenance dosage, the maintenance dosage may be reduced to 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “If you miss doses of WEGOVY for more than 2 weeks, take your next dose on the regularly scheduled day or call your healthcare provider to talk about how to restart your treatment.”missed dose · touches the two card lines on missed dose
    • “Initiate WEGOVY according to the dosage escalation schedule in Table 2 to minimize gastrointestinal adverse reactions [see Adverse Reactions”dose increase · touches the seven card lines on dose increase
    • “Recommended Dosage Regimen for Adults”dose schedule · touches the three card lines on dose schedule
    • “Recommended Dosage Regimen for Pediatric Patients Aged 12 Years and Older”dose schedule · touches the three card lines on dose schedule
    • “The 0.25 mg, 0.5 mg, and 1 mg once-weekly dosages are initiation and escalation dosages and are not approved as maintenance dosages.”dose increase · touches the seven card lines on dose increase
    • “The maintenance dosage of WEGOVY in adults is either 2.4 mg (recommended) or 1.7 mg once weekly (2.2) .”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The maintenance dosage of WEGOVY in adults is either 2.4 mg (recommended) or 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The maintenance dosage of WEGOVY in pediatric patients aged 12 years and older is 2.4 mg once weekly (2.3).”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The maintenance dosage of WEGOVY in pediatric patients aged 12 years and older is 2.4 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “Then follow the dose escalation schedule presented in Table 1 to minimize gastrointestinal adverse reactions [see Adverse Reactions (”dose increase · touches the seven card lines on dose increase
    • “These reactions increased during dose escalation.”dose increase · touches the seven card lines on dose increase
    • “a Not approved as maintenance dosages”dose increase · touches the seven card lines on dose increase

    New in the label

    • “2.2 Recommended Dosage in Adults and Pediatric Patients Aged 12 Years and Older”dose schedule · touches the three card lines on dose schedule
    • “2.3 Recommendations Regarding Missed Dose”missed dose · touches the two card lines on missed dose
    • “Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (”dose increase · touches the seven card lines on dose increase
    • “Follow the dosage initiation and escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] .”dose increase · touches the seven card lines on dose increase
    • “If you miss doses of WEGOVY for 2 or more weeks, take your next dose on the regularly scheduled day or call your healthcare provider to talk about how to restart your treatment.”missed dose · touches the two card lines on missed dose
    • “Recommended Dosage Escalation in Adults and Pediatric Patients Aged 12 Years and Older”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly (2.2) .”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly.”dose schedule, dose increase · touches the 10 card lines on dose schedule and dose increase
    • “The recommended dosage of WEGOVY in patients with hepatic impairment is the same as those with normal hepatic function.”dose schedule · touches the three card lines on dose schedule
    • “These reactions were most frequently reported during dosage escalation.”dose increase · touches the seven card lines on dose increase

Mounjaro (tirzepatide)

15 label versions since January 2024; 8 changed the wording this site quotes, most recently August 27, 2026.

What the current label says

The per-pen card's lines

  • Device (two card lines): changed in three versions, most recently August 27, 2026.
  • Dose schedule (three card lines): changed in three versions, most recently August 27, 2026.
  • Dose increase (two card lines): changed in three versions, most recently August 27, 2026.
  • Missed dose (one card line): changed in one version, most recently August 27, 2026.
  • Storage out of fridge (two card lines): changed in four versions, most recently August 27, 2026.
  • August 27, 2026 (label version 40, published on DailyMed Sep 02, 2026; this version)

    No longer in the label

    • “After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.”dose schedule, dose increase · touches the five card lines on dose schedule and dose increase
    • “After 4 weeks, increase to 5 mg injected subcutaneously once weekly.”dose schedule · touches the three card lines on dose schedule
    • “Discard single-dose pen and single-dose vial after a total of 21 days at room temperature.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )] .”dose increase · touches the two card lines on dose increase
    • “Inject MOUNJARO subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.”injection site
    • “Inject subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.”injection site
    • “Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial or single-patient-use KwikPen ® ( 3 )”device · touches the two card lines on device
    • “Injection: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial ( 3 )”device · touches the two card lines on device

    New in the label

    • “Discard the single-dose pen or single-dose vial after a total of 21 days at room temperature.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Follow the starting dosage recommendation and dosage escalation schedule below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )].”dose schedule, dose increase · touches the five card lines on dose schedule and dose increase
    • “Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm.”injection site
    • “Inject subcutaneously in the abdomen, thigh, or have another person inject in the back of the upper arm.”injection site
    • “Multi-dose vial or single-patient-use KwikPen ® : 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL ( 3 )”device · touches the two card lines on device
    • “Recommendations Regarding Missed Doses”missed dose · touches the card line on missed dose
    • “Recommended Starting Dosage and Escalation”dose schedule, dose increase · touches the five card lines on dose schedule and dose increase
    • “Single-dose pen or single-dose vial: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, or 15 mg/0.5 mL ( 3 )”device · touches the two card lines on device · the card quotes these words today
  • April 22, 2026 (label version 38, published on DailyMed May 06, 2026; this version)

    No longer in the label

    • “If needed, each single-dose pen or single-dose vial can be stored at room temperature up to 86⁰F (30⁰C) for up to 21 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to 21 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab.”injection site
    • “You may store the unopened vial at room temperature up to 86°F (30°C) for up to 21 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “You may store your Pen at room temperature up to 86°F (30°C) for up to 21 days.”storage out of fridge · touches the two card lines on storage out of fridge

    New in the label

    • “Discard single-dose pen and single-dose vial after a total of 21 days at room temperature.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Discard the Pen after a total of 21 days at room temperature.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Discard the vial after a total of 21 days at room temperature.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If needed, each single-dose pen or single-dose vial can be stored at room temperature up to 86⁰F (30⁰C) for up to a total of 21 days.”storage out of fridge · touches the two card lines on storage out of fridge · the card quotes these words today
    • “If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away single-dose pen or single-dose vial after a total of 21 days at room temperature.”storage out of fridge · touches the two card lines on storage out of fridge · the card quotes these words today
    • “You may store the unopened vial at room temperature up to 86°F (30°C) for up to a total of 21 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “You may store your Pen at room temperature up to 86°F (30°C) for up to a total of 21 days.”storage out of fridge · touches the two card lines on storage out of fridge
  • January 20, 2026 (label version 35, published on DailyMed Feb 09, 2026; this version)

    No longer in the label

    • “10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses”device · touches the two card lines on device
    • “20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses”device · touches the two card lines on device
    • “30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses”device · touches the two card lines on device
    • “40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses”device · touches the two card lines on device
    • “50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses”device · touches the two card lines on device
    • “60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses”device · touches the two card lines on device
    • “If stored at room temperature [up to 30°C (86°F)], throw away unopened vial after 30 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial ( 3 )”device · touches the two card lines on device
    • “Store multi-dose vial in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store opened (in-use) vial in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store unopened vial in the refrigerator at 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the two card lines on storage out of fridge
    • “The unopened vial can be used until the expiration date on the label if kept in the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medication left in it.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away the multi-dose vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if it still has medicine in it.”storage out of fridge · touches the two card lines on storage out of fridge

    New in the label

    • “2.1 Recommended Dosage”dose schedule · touches the three card lines on dose schedule
    • “Choose an injection site.”injection site
    • “If stored at room temperature [up to 30°C (86°F)], throw away unopened multi-dose vial or single-patient-use KwikPen after 30 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If you see blood after you pull the needle out of your skin, lightly press the injection site with gauze or a cotton ball.”injection site
    • “Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial or single-patient-use KwikPen ® ( 3 )”device · touches the two card lines on device
    • “Recommended Dosage ( 2.1 )”dose schedule · touches the three card lines on dose schedule
    • “Store multi-dose vial or single-patient-use KwikPen in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”storage out of fridge · touches the two card lines on storage out of fridge · the card quotes these words today
    • “Store opened (in-use) multi-dose vial or single-patient-use KwikPen in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store unopened multi-dose vial or single-patient-use KwikPen in the refrigerator at 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store unused Pens in the refrigerator between 36°F to 46°F (2°C to 8°C).”storage out of fridge · touches the two card lines on storage out of fridge
    • “The unopened multi-dose vial or single-patient-use KwikPen can be used until the expiration date on the label if kept in the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away opened multi-dose vial or single-patient-use KwikPen after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away the multi-dose vial or single-patient-use KwikPen after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if it still has medicine in it.”storage out of fridge · touches the two card lines on storage out of fridge · the card quotes these words today
    • “Unused Pens may be used until the expiration date (EXP) printed on the label if the Pen has been kept in the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Use MOUNJARO KwikPen once weekly”dose schedule · touches the three card lines on dose schedule
    • “Write the day of the week you choose to inject.”dose schedule · touches the three card lines on dose schedule
    • “You may store your used Pen at room temperature up to 86°F (30°C) after your injection.”storage out of fridge · touches the two card lines on storage out of fridge
    • “You or another person can inject the medicine in your thigh or stomach (abdomen) at least 2 inches from the belly button.”injection site
  • January 7, 2026 (label version 34, published on DailyMed Jan 26, 2026; this version)

    No longer in the label

    • “Store MOUNJARO in a refrigerator at 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store MOUNJARO in the refrigerator between 36°F to 46°F (2°C to 8°C).”storage out of fridge · touches the two card lines on storage out of fridge

    New in the label

    • “10 mg/2.4 mL (4.17 mg/mL)”device · touches the two card lines on device
    • “10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses”device · touches the two card lines on device · the card quotes these words today
    • “20 mg/2.4 mL (8.33 mg/mL)”device · touches the two card lines on device
    • “20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses”device · touches the two card lines on device · the card quotes these words today
    • “30 mg/2.4 mL (12.5 mg/mL)”device · touches the two card lines on device
    • “30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses”device · touches the two card lines on device · the card quotes these words today
    • “4 doses of 10 mg/0.6 mL”device · touches the two card lines on device
    • “4 doses of 12.5 mg/0.6 mL”device · touches the two card lines on device
    • “4 doses of 15 mg/0.6 mL”device · touches the two card lines on device
    • “4 doses of 2.5 mg/0.6 mL”device · touches the two card lines on device
    • “4 doses of 5 mg/0.6 mL”device · touches the two card lines on device
    • “4 doses of 7.5 mg/0.6 mL”device · touches the two card lines on device
    • “40 mg/2.4 mL (16.7 mg/mL)”device · touches the two card lines on device
    • “40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses”device · touches the two card lines on device · the card quotes these words today
    • “50 mg/2.4 mL (20.8 mg/mL)”device · touches the two card lines on device
    • “50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses”device · touches the two card lines on device · the card quotes these words today
    • “60 mg/2.4 mL (25 mg/mL)”device · touches the two card lines on device
    • “60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses”device · touches the two card lines on device
    • “If stored at room temperature [up to 30°C (86°F)], throw away unopened vial after 30 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If stored at room temperature [up to 86°F (30°C)], throw away unopened vial after 30 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze.”injection site
    • “Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial ( 3 )”device · touches the two card lines on device
    • “It can be used until the expiration date on the label if kept in the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store MOUNJARO single-dose pen and single-dose vial in a refrigerator at 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store each single-dose pen or single-dose vial in the refrigerator between 36⁰F to 46⁰F (2⁰C to 8⁰C).”storage out of fridge · touches the two card lines on storage out of fridge · the card quotes these words today
    • “Store multi-dose vial in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store opened (in-use) vial in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store opened (in-use) vial in the original carton in the refrigerator at 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store unopened vial in the refrigerator at 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store unopened vial in the refrigerator at 36°F to 46°F (2°C to 8°C).”storage out of fridge · touches the two card lines on storage out of fridge
    • “The unopened vial can be used until the expiration date on the label if kept in the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medication left in it.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away the multi-dose vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if it still has medicine in it.”storage out of fridge · touches the two card lines on storage out of fridge
  • December 19, 2025 (label version 33, published on DailyMed Dec 31, 2025; this version)

    No longer in the label

    • “Inject subcutaneously in the abdomen, thigh, or upper arm.”injection site
    • “The maximum dosage is 15 mg subcutaneously once weekly.”dose schedule, dose increase · touches the five card lines on dose schedule and dose increase
    • “The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.”dose schedule, dose increase · touches the five card lines on dose schedule and dose increase

    New in the label

    • “10 mg injected subcutaneously once weekly in pediatric patients.”dose schedule · touches the three card lines on dose schedule
    • “15 mg injected subcutaneously once weekly in adults.”dose schedule · touches the three card lines on dose schedule
    • “Adults: 15 mg subcutaneously once weekly.”dose schedule · touches the three card lines on dose schedule
    • “Inject subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.”injection site
    • “Maximum dosage ( 2.1 ):”dose increase · touches the two card lines on dose increase
    • “Pediatric patients 10 years of age and older: 10 mg subcutaneously once weekly.”dose schedule · touches the three card lines on dose schedule
    • “The maximum dosage of MOUNJARO is:”dose increase · touches the two card lines on dose increase · the card quotes these words today
  • October 24, 2025 (label version 31, published on DailyMed Nov 17, 2025; this version)

    No longer in the label

    • “Inject MOUNJARO subcutaneously in the abdomen, thigh, or upper arm.”injection site
    • “Inject MOUNJARO under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”injection site

    New in the label

    • “Inject MOUNJARO subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.”injection site
    • “Inject MOUNJARO under the skin (subcutaneously) of your stomach (abdomen), thigh, or another person should inject in the back of the upper arm.”injection site
  • May 28, 2025 (label version 24, published on DailyMed Jun 13, 2025; this version)

    No longer in the label

    • “MOUNJARO is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”injection site

    New in the label

    • “Inject MOUNJARO under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”injection site
  • November 1, 2024 (label version 18, published on DailyMed Nov 21, 2024; this version)

    New in the label

    • “Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )] .”dose increase · touches the two card lines on dose increase

Zepbound (tirzepatide)

20 label versions since January 2024; 9 changed the wording this site quotes, most recently August 28, 2026.

What the current label says

The per-pen card's lines

  • Device (two card lines): changed in five versions, most recently August 28, 2026.
  • Dose schedule (four card lines): changed in three versions, most recently January 20, 2026.
  • Dose increase (four card lines): changed in two versions, most recently December 20, 2024.
  • Missed dose (one card line): changed in two versions, most recently December 20, 2024.
  • Storage out of fridge (two card lines): changed in three versions, most recently April 22, 2026.
  • August 28, 2026 (label version 40, published on DailyMed Sep 02, 2026; this version)

    No longer in the label

    • “Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial or single-patient-use KwikPen ® ( 3 )”device · touches the two card lines on device
    • “Injection: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial ( 3 )”device · touches the two card lines on device

    New in the label

    • “Multi-dose vial or single-patient-use KwikPen ® : 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL ( 3 )”device · touches the two card lines on device
    • “Single-dose pen or single-dose vial: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, or 15 mg/0.5 mL ( 3 )”device · touches the two card lines on device · the card quotes these words today
  • April 22, 2026 (label version 38, published on DailyMed May 06, 2026; this version)

    No longer in the label

    • “Discard single-dose pen and single-dose vial if not used within 21 days after removing from the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Discard the pen if not used within 21 days after removing from the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If needed, each single-dose pen or single-dose vial can be stored at room temperature up to 86°F (30°C) for up to 21 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to 21 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If single-dose pen or single-dose vial is stored at room temperature, it should not be returned to the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab.”injection site
    • “If you store the pen at room temperature, do not return the pen to the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away single-dose pen or single-dose vial if not used within 21 days after removing from the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “You may store the unopened vial at room temperature up to 86°F (30°C) for up to 21 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “You may store your pen at room temperature up to 86°F (30°C) for up to 21 days.”storage out of fridge · touches the two card lines on storage out of fridge

    New in the label

    • “Discard single-dose pen and single-dose vial after a total of 21 days at room temperature.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Discard the pen after a total of 21 days at room temperature.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Discard the vial after a total of 21 days at room temperature.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If needed, each single-dose pen or single-dose vial can be stored at room temperature up to 86°F (30°C) for up to a total of 21 days.”storage out of fridge · touches the two card lines on storage out of fridge · the card quotes these words today
    • “If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away single-dose pen or single-dose vial after a total of 21 days at room temperature.”storage out of fridge · touches the two card lines on storage out of fridge · the card quotes these words today
    • “You may store the unopened vial at room temperature up to 86°F (30°C) for up to a total of 21 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “You may store your pen at room temperature up to 86°F (30°C) for up to a total of 21 days.”storage out of fridge · touches the two card lines on storage out of fridge
  • January 20, 2026 (label version 32, published on DailyMed Feb 05, 2026; this version)

    No longer in the label

    • “10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses”device · touches the two card lines on device
    • “20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses”device · touches the two card lines on device
    • “30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses”device · touches the two card lines on device
    • “40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses”device · touches the two card lines on device
    • “50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses”device · touches the two card lines on device
    • “60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses”device · touches the two card lines on device
    • “If stored at room temperature [up to 30°C (86°F)], throw away unopened vial after 30 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial ( 3 )”device · touches the two card lines on device
    • “Store multi-dose vial in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store opened (in-use) vial in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store unopened vial in the refrigerator at 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the two card lines on storage out of fridge
    • “The unopened vial can be used until the expiration date on the label if kept in the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medication left in it.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away the multi-dose vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if it still has medicine in it.”storage out of fridge · touches the two card lines on storage out of fridge

    New in the label

    • “Choose an injection site.”injection site
    • “If stored at room temperature [up to 30°C (86°F)], throw away unopened multi-dose vial or single-patient-use KwikPen after 30 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If you see blood after you pull the needle out of your skin, lightly press the injection site with gauze or a cotton ball.”injection site
    • “Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial or single-patient-use KwikPen ® ( 3 )”device · touches the two card lines on device
    • “Store multi-dose vial or single-patient-use KwikPen in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”storage out of fridge · touches the two card lines on storage out of fridge · the card quotes these words today
    • “Store opened (in-use) multi-dose vial or single-patient-use KwikPen in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store unopened multi-dose vial or single-patient-use KwikPen in the refrigerator at 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store unused Pens in the refrigerator between 36°F to 46°F (2°C to 8°C).”storage out of fridge · touches the two card lines on storage out of fridge
    • “The unopened multi-dose vial or single-patient-use KwikPen can be used until the expiration date on the label if kept in the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away opened multi-dose vial or single-patient-use KwikPen after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away the multi-dose vial or single-patient-use KwikPen after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if it still has medicine in it.”storage out of fridge · touches the two card lines on storage out of fridge · the card quotes these words today
    • “Unused Pens may be used until the expiration date (EXP) printed on the label if the Pen has been kept in the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Use ZEPBOUND KwikPen once weekly”dose schedule · touches the four card lines on dose schedule
    • “Write the day of the week you choose to inject.”dose schedule · touches the four card lines on dose schedule
    • “You may store your used Pen at room temperature up to 86°F (30°C) after your injection.”storage out of fridge · touches the two card lines on storage out of fridge
    • “You or another person can inject the medicine in your thigh or stomach (abdomen) at least 2 inches from the belly button.”injection site
  • January 7, 2026 (label version 31, published on DailyMed Jan 23, 2026; this version)

    No longer in the label

    • “Discard if not used within 21 days after removing from the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If ZEPBOUND is stored at room temperature, it should not be returned to the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store ZEPBOUND in a refrigerator at 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store ZEPBOUND in the refrigerator between 36°F to 46°F (2°C to 8°C).”storage out of fridge · touches the two card lines on storage out of fridge

    New in the label

    • “10 mg/2.4 mL (4.17 mg/mL)”device · touches the two card lines on device
    • “10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses”device · touches the two card lines on device · the card quotes these words today
    • “20 mg/2.4 mL (8.33 mg/mL)”device · touches the two card lines on device
    • “20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses”device · touches the two card lines on device · the card quotes these words today
    • “30 mg/2.4 mL (12.5 mg/mL)”device · touches the two card lines on device
    • “30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses”device · touches the two card lines on device · the card quotes these words today
    • “4 doses of 10 mg/0.6 mL”device · touches the two card lines on device
    • “4 doses of 12.5 mg/0.6 mL”device · touches the two card lines on device
    • “4 doses of 15 mg/0.6 mL”device · touches the two card lines on device
    • “4 doses of 2.5 mg/0.6 mL”device · touches the two card lines on device
    • “4 doses of 5 mg/0.6 mL”device · touches the two card lines on device
    • “4 doses of 7.5 mg/0.6 mL”device · touches the two card lines on device
    • “40 mg/2.4 mL (16.7 mg/mL)”device · touches the two card lines on device
    • “40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses”device · touches the two card lines on device · the card quotes these words today
    • “50 mg/2.4 mL (20.8 mg/mL)”device · touches the two card lines on device
    • “50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses”device · touches the two card lines on device · the card quotes these words today
    • “60 mg/2.4 mL (25 mg/mL)”device · touches the two card lines on device
    • “60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses”device · touches the two card lines on device
    • “Discard single-dose pen and single-dose vial if not used within 21 days after removing from the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If single-dose pen or single-dose vial is stored at room temperature, it should not be returned to the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If stored at room temperature [up to 30°C (86°F)], throw away unopened vial after 30 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If stored at room temperature [up to 86°F (30°C)], throw away unopened vial after 30 days.”storage out of fridge · touches the two card lines on storage out of fridge
    • “If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze.”injection site
    • “Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial ( 3 )”device · touches the two card lines on device
    • “It can be used until the expiration date on the label if kept in the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store ZEPBOUND single-dose pen and single-dose vial in a refrigerator at 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store multi-dose vial in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store opened (in-use) vial in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store opened (in-use) vial in the original carton in the refrigerator at 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store single-dose pen and single-dose vial in the refrigerator between 36°F to 46°F (2°C to 8°C).”storage out of fridge · touches the two card lines on storage out of fridge · the card quotes these words today
    • “Store unopened vial in the refrigerator at 2°C to 8°C (36°F to 46°F).”storage out of fridge · touches the two card lines on storage out of fridge
    • “Store unopened vial in the refrigerator at 36°F to 46°F (2°C to 8°C).”storage out of fridge · touches the two card lines on storage out of fridge
    • “The unopened vial can be used until the expiration date on the label if kept in the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medication left in it.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away single-dose pen or single-dose vial if not used within 21 days after removing from the refrigerator.”storage out of fridge · touches the two card lines on storage out of fridge
    • “Throw away the multi-dose vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if it still has medicine in it.”storage out of fridge · touches the two card lines on storage out of fridge
  • October 24, 2025 (label version 28, published on DailyMed Nov 17, 2025; this version)

    No longer in the label

    • “Inject ZEPBOUND subcutaneously in the abdomen, thigh, or upper arm.”injection site
    • “ZEPBOUND is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”injection site

    New in the label

    • “Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.”injection site
    • “Inject ZEPBOUND under the skin (subcutaneously) of your stomach (abdomen), thigh, or another person should inject in the back of the upper arm.”injection site
  • March 12, 2025 (label version 18, published on DailyMed Mar 21, 2025; this version)

    No longer in the label

    • “4 x 2.5 mg/0.5 mL single-dose vials”device · touches the two card lines on device
    • “4 x 5 mg/0.5 mL single-dose vials”device · touches the two card lines on device
  • December 20, 2024 (label version 15, published on DailyMed Jan 06, 2025; this version)

    No longer in the label

    • “2.1 Recommended Dosage”dose schedule · touches the four card lines on dose schedule
    • “2.2 Recommendations Regarding Missed Dose”missed dose · touches the card line on missed dose
    • “Administer once weekly at any time of day, with or without meals.”dose schedule · touches the four card lines on dose schedule
    • “After 4 weeks, increase to 5 mg injected subcutaneously once weekly.”dose schedule · touches the four card lines on dose schedule
    • “Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 )] .”dose increase · touches the four card lines on dose increase
    • “Increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.”dose increase · touches the four card lines on dose increase
    • “Inject subcutaneously in the abdomen, thigh, or upper arm.”injection site
    • “The maximum dosage is 15 mg subcutaneously once weekly.”dose schedule, dose increase · touches the eight card lines on dose schedule and dose increase
    • “The maximum dosage of ZEPBOUND is 15 mg injected subcutaneously once weekly.”dose schedule, dose increase · touches the eight card lines on dose schedule and dose increase
    • “The recommended maintenance dosages are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.”dose schedule, dose increase · touches the eight card lines on dose schedule and dose increase
    • “The recommended maintenance dosages of ZEPBOUND in adults are 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”dose schedule, dose increase · touches the eight card lines on dose schedule and dose increase
    • “The recommended starting dosage is 2.5 mg injected subcutaneously once weekly.”dose schedule · touches the four card lines on dose schedule
    • “The recommended starting dosage of ZEPBOUND is 2.5 mg injected subcutaneously once weekly.”dose schedule · touches the four card lines on dose schedule

    New in the label

    • “2.1 Recommended Dose Escalation Schedule”dose increase · touches the four card lines on dose increase
    • “2.2 Recommended Maintenance and Maximum Dosage”dose increase · touches the four card lines on dose increase
    • “2.3 Recommendations Regarding Missed Dose”missed dose · touches the card line on missed dose
    • “Follow the dosage escalation below for all indications to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 )] .”dose increase · touches the four card lines on dose increase
    • “Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved.”dose increase · touches the four card lines on dose increase
    • “Maximum Recommended Dosage”dose schedule, dose increase · touches the eight card lines on dose schedule and dose increase
    • “Maximum Recommended Dosage: 15 mg injected subcutaneously once weekly.”dose schedule, dose increase · touches the eight card lines on dose schedule and dose increase
    • “Obstructive Sleep Apnea: 10 mg or 15 mg injected subcutaneously once weekly.”dose schedule · touches the four card lines on dose schedule
    • “Recommended Dose Escalation Schedule”dose increase · touches the four card lines on dose increase
    • “Recommended Maintenance Dosage”dose increase · touches the four card lines on dose increase
    • “Recommended Maintenance and Maximum Dosage”dose increase · touches the four card lines on dose increase
    • “The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly.”dose schedule, dose increase · touches the eight card lines on dose schedule and dose increase · the card quotes these words today
    • “The recommended maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly.”dose schedule, dose increase · touches the eight card lines on dose schedule and dose increase · the card quotes these words today
    • “The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”dose schedule, dose increase · touches the eight card lines on dose schedule and dose increase · the card quotes these words today
    • “The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks.”dose schedule · touches the four card lines on dose schedule
    • “The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks.”dose schedule · touches the four card lines on dose schedule · the card quotes these words today
    • “Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.”dose schedule · touches the four card lines on dose schedule
  • October 23, 2024 (label version 12, published on DailyMed Nov 04, 2024; this version)

    No longer in the label

    • “2.2 Recommended Dosage”dose schedule · touches the four card lines on dose schedule
    • “2.3 Recommendations Regarding Missed Dose”missed dose · touches the card line on missed dose

    New in the label

    • “2.1 Recommended Dosage”dose schedule · touches the four card lines on dose schedule
    • “2.2 Recommendations Regarding Missed Dose”missed dose · touches the card line on missed dose
    • “Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 )] .”dose increase · touches the four card lines on dose increase
    • “For Studies 1 and 2, weight reduction was assessed after 72 weeks of treatment (at least 52 weeks at maintenance dose).”dose increase · touches the four card lines on dose increase
    • “The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”dose increase · touches the four card lines on dose increase
    • “Weight reduction was assessed after 72 weeks of treatment (at least 52 weeks at maintenance dose).”dose increase · touches the four card lines on dose increase
  • May 23, 2024 (label version 8, published on DailyMed Aug 08, 2024; this version)

    New in the label

    • “4 x 2.5 mg/0.5 mL single-dose vials”device · touches the two card lines on device
    • “4 x 5 mg/0.5 mL single-dose vials”device · touches the two card lines on device

Trulicity (dulaglutide)

7 label versions since January 2024; 2 changed the wording this site quotes, most recently May 28, 2025.

The per-pen card's lines

  • Dose schedule (three card lines): changed in one version, most recently November 1, 2024.
  • Dose increase (four card lines): changed in one version, most recently November 1, 2024.
  • Missed dose (one card line): no change in this period.
  • Storage out of fridge (two card lines): no change in this period.
  • May 28, 2025 (label version 56, published on DailyMed Jun 09, 2025; this version)

    No longer in the label

    • “TRULICITY is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”injection site

    New in the label

    • “Inject TRULICITY under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”injection site
  • November 1, 2024 (label version 54, published on DailyMed Nov 14, 2024; this version)

    No longer in the label

    • “If additional glycemic control is needed, increase the dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage.”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase
    • “Increase dosage to 1.5 mg once weekly for additional glycemic control.”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase
    • “Increase the dosage to 1.5 mg once weekly for additional glycemic control.”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase

    New in the label

    • “After 4 weeks, the dosage may be increased to 1.5 mg once weekly for additional glycemic control.”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase · the card quotes these words today
    • “Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )].”dose increase · touches the four card lines on dose increase
    • “If additional glycemic control is needed, increase the dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )] .”dose schedule, dose increase · touches the seven card lines on dose schedule and dose increase

Bydureon BCise (exenatide extended-release)

Discontinued FDA lists it as discontinued (Drugs@FDA, application NDA209210, checked November 10, 2026). Its label page is still on DailyMed. Drugs@FDA

Source: Drugs@FDA, via openFDA. Do not rely on openFDA to make decisions regarding medical care; check with your pharmacy.

2 label versions since January 2024; 1 changed the wording this site quotes, most recently May 28, 2025.

DailyMed did not serve the current label file on 2026-10-06 (HTTP 404 for https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=2d18cfc4-e0de-4814-a712-c1b7c504bff5&type=zip); the record ends at the newest archived version.

The per-pen card's lines

  • Dose schedule (two card lines): changed in one version, most recently May 28, 2025.
  • Missed dose (one card line): no change in this period.
  • Storage out of fridge (two card lines): no change in this period.
  • May 28, 2025 (label version 39, published on DailyMed Jun 05, 2025; this version)

    No longer in the label

    • “BYDUREON BCISE is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”injection site

    New in the label

    • “Inject BYDUREON BCISE under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”injection site
    • “It is acceptable to inject BYDUREON BCISE and insulin in the same body region, but the injections should not be adjacent to each other.”injection site
    • “Treatment with BYDUREON 2 mg once weekly (QW) resulted in mean HbA 1c reduction that was statistically significantly greater compared to sitagliptin 100 mg/day.”dose schedule · touches the two card lines on dose schedule
    • “Treatment with BYDUREON BCISE 2 mg once weekly (QW) resulted in a statistically significantly greater reduction in HbA 1c compared to BYETTA 10 mcg twice daily.”dose schedule · touches the two card lines on dose schedule

Victoza (liraglutide)

4 label versions since January 2024; 3 changed the wording this site quotes, most recently October 14, 2025.

The per-pen card's lines

  • Dose schedule (three card lines): changed in one version, most recently May 1, 2025.
  • Dose increase (four card lines): changed in one version, most recently May 1, 2025.
  • Missed dose (two card lines): no change in this period.
  • Storage out of fridge (four card lines): changed in three versions, most recently October 14, 2025.
  • October 14, 2025 (label version 31, published on DailyMed Nov 17, 2025; this version)

    No longer in the label

    • “Injection: 18 mg/3 mL (6 mg/mL) clear, colorless solution in a pre-filled, single-patient-use pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg.”device · on device; the card quotes no line of this kind
    • “Store your Victoza pen at 59ºF to 86ºF (15ºC to 30ºC), or in a refrigerator at 36ºF to 46ºF (2°C to 8°C).”storage out of fridge · touches the four card lines on storage out of fridge
    • “Store your new, unused Victoza pen in the refrigerator at 36ºF to 46ºF (2ºC to 8ºC).”storage out of fridge · touches the four card lines on storage out of fridge

    New in the label

    • “Choose your injection site in either the stomach (abdomen), thigh, or upper arm (only if caregiver administered) and wipe the skin with an alcohol swab (See Figure M ).”injection site
    • “Injection: 18 mg/3 mL (6 mg/mL) clear, colorless solution in a prefilled, single-patient-use pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg.”device · on device; the card quotes no line of this kind
    • “Let the injection site dry before you inject your dose.”injection site
    • “Store your Victoza pen at room temperature between 59ºF to 86ºF (15ºC to 30ºC), or in a refrigerator between 36ºF to 46ºF (2°C to 8°C).”storage out of fridge · touches the four card lines on storage out of fridge · the card quotes these words today
    • “Store your new, unused Victoza pen in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).”storage out of fridge · touches the four card lines on storage out of fridge · the card quotes these words today
    • “When carrying the pen away from home, store the pen at room temperature between 59ºF to 86ºF (15ºC to 30ºC).”storage out of fridge · touches the four card lines on storage out of fridge
  • May 1, 2025 (label version 30, published on DailyMed Jun 12, 2025; this version)

    No longer in the label

    • “Change (rotate) your injection site within the area you choose with each injection to reduce your risk of getting lumps under the skin (cutaneous amyloidosis).”injection site
    • “Choose your injection site in either the stomach (abdomen), thigh, or upper arm (only if caregiver administered) and wipe the skin with an alcohol swab (See Figure M ).”injection site
    • “If additional glycemic control is required, increase the dosage in 0.6 mg increments after at least one week on the current dosage.”dose increase · touches the four card lines on dose increase
    • “If more than 3 days have elapsed since the last VICTOZA dose, reinitiate VICTOZA at 0.6 mg once daily to mitigate any gastrointestinal symptoms associated with reinitiation of treatment.”dose schedule · touches the three card lines on dose schedule
    • “Let the injection site dry before you inject your dose.”injection site
    • “Store your Victoza pen at room temperature between 59ºF to 86ºF (15ºC to 30ºC), or in a refrigerator between 36ºF to 46ºF (2°C to 8°C).”storage out of fridge · touches the four card lines on storage out of fridge
    • “Store your new, unused Victoza pen in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).”storage out of fridge · touches the four card lines on storage out of fridge
    • “The 0.6 mg once daily dosage is intended to reduce gastrointestinal symptoms [see Adverse Reactions (6.1)] during initial titration and is not effective for glycemic control in adults.”dose schedule · touches the three card lines on dose schedule
    • “Use caution when initiating or escalating doses of VICTOZA in patients with renal impairment (5.5) .”dose increase · touches the four card lines on dose increase
    • “Use caution when initiating or escalating doses of VICTOZA in patients with renal impairment [see Use in Specific Populations ( 8.6 )] .”dose increase · touches the four card lines on dose increase
    • “VICTOZA is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”injection site
    • “When carrying the pen away from home, store the pen at room temperature between 59ºF to 86ºF (15ºC to 30ºC).”storage out of fridge · touches the four card lines on storage out of fridge

    New in the label

    • “Change (rotate) your injection site with each injection.”injection site
    • “If additional glycemic control is required, increase the dosage in 0.6 mg increments after at least one week on the current dosage, to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )] .”dose increase · touches the four card lines on dose increase
    • “If more than 3 days have elapsed since the last VICTOZA dose, reinitiate VICTOZA at 0.6 mg once daily to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment.”dose schedule · touches the three card lines on dose schedule
    • “Inject your dose of VICTOZA under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”injection site
    • “Store your Victoza pen at 59ºF to 86ºF (15ºC to 30ºC), or in a refrigerator at 36ºF to 46ºF (2°C to 8°C).”storage out of fridge · touches the four card lines on storage out of fridge
    • “Store your new, unused Victoza pen in the refrigerator at 36ºF to 46ºF (2ºC to 8ºC).”storage out of fridge · touches the four card lines on storage out of fridge
    • “The 0.6 mg once daily dosage is intended to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)] during initial titration and is not effective for glycemic control in adults.”dose schedule · touches the three card lines on dose schedule
  • February 3, 2025 (label version 29, published on DailyMed Feb 24, 2025; this version)

    No longer in the label

    • “Store your Victoza pen at 59ºF to 86ºF (15ºC to 30ºC), or in a refrigerator at 36ºF to 46ºF (2°C to 8°C).”storage out of fridge · touches the four card lines on storage out of fridge
    • “Store your new, unused Victoza pen in the refrigerator at 36ºF to 46ºF (2ºC to 8ºC).”storage out of fridge · touches the four card lines on storage out of fridge

    New in the label

    • “Choose your injection site in either the stomach (abdomen), thigh, or upper arm (only if caregiver administered) and wipe the skin with an alcohol swab (See Figure M ).”injection site
    • “Let the injection site dry before you inject your dose.”injection site
    • “Store your Victoza pen at room temperature between 59ºF to 86ºF (15ºC to 30ºC), or in a refrigerator between 36ºF to 46ºF (2°C to 8°C).”storage out of fridge · touches the four card lines on storage out of fridge · the card quotes these words today
    • “Store your new, unused Victoza pen in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).”storage out of fridge · touches the four card lines on storage out of fridge · the card quotes these words today
    • “When carrying the pen away from home, store the pen at room temperature between 59ºF to 86ºF (15ºC to 30ºC).”storage out of fridge · touches the four card lines on storage out of fridge

Saxenda (liraglutide)

5 label versions since January 2024; 3 changed the wording this site quotes, most recently February 25, 2026.

The per-pen card's lines

  • Dose schedule (one card line): changed in one version, most recently May 1, 2025.
  • Dose increase (one card line): changed in two versions, most recently October 14, 2025.
  • Missed dose (one card line): no change in this period.
  • Storage out of fridge (three card lines): no change in this period.
  • February 25, 2026 (label version 22, published on DailyMed Jun 15, 2026; this version)

    No longer in the label

    • “If blood appears at the injection site, press lightly.”injection site

    New in the label

    • “Choose your injection site and wipe the skin with an alcohol swab.”injection site
    • “If blood appears at the injection site, press lightly with a cotton ball or gauze.”injection site
    • “Let the injection site dry before you inject your dose.”injection site
  • October 14, 2025 (label version 20, published on DailyMed Nov 17, 2025; this version)

    No longer in the label

    • “Dose Escalation Schedule”dose increase · touches the card line on dose increase

    New in the label

    • “Dosage Escalation Schedule”dose increase · touches the card line on dose increase
  • May 1, 2025 (label version 19, published on DailyMed Jun 12, 2025; this version)

    No longer in the label

    • “Change (rotate) your injection site within the area you choose with each injection to reduce your risk of getting lumps under the skin (cutaneous amyloidosis).”injection site
    • “For adults, the recommended dosage of SAXENDA is 3 mg daily, lower doses are for titration only.”dose schedule · touches the card line on dose schedule
    • “If more than 3 days have elapsed since the last SAXENDA dose, reinitiate SAXENDA at 0.6 mg daily and follow the dose escalation schedule in Table 3, to reduce the occurrence of gastrointestinal adverse reactions associated with reinitiation of treatment.”dose increase · touches the card line on dose increase
    • “If patients do not tolerate an increased dose during dose escalation, consider delaying dose escalation for approximately one additional week.”dose increase · touches the card line on dose increase
    • “Inject your dose of SAXENDA under the skin (subcutaneously) in your stomach area (abdomen), upper leg (thigh), or upper arm, as instructed by your healthcare provider.”injection site
    • “No dose adjustment is needed if changing the injection site and/or timing.”injection site
    • “Table 3: Dose Escalation Schedule”dose increase · touches the card line on dose increase
    • “The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 0.9-1.4 L/h with an elimination half-life of approximately 13 hours, making liraglutide suitable for once daily administration.”dose schedule · touches the card line on dose schedule
    • “Then follow the dose escalation schedule in Table 3 to minimize gastrointestinal adverse reactions [see Adverse Reactions ( 6.1 )] .”dose increase · touches the card line on dose increase
    • “Use caution when initiating or escalating doses of SAXENDA in patients with renal impairment ( 5.6 ).”dose increase · touches the card line on dose increase
    • “Use caution when initiating or escalating doses of SAXENDA in patients with renal impairment [see Use in Specific Populations ( 8.6 )] .”dose increase · touches the card line on dose increase

    New in the label

    • “Change (rotate) your injection site with each injection.”injection site
    • “Dosage escalation for pediatric patients may take up to 8 weeks.”dose increase · touches the card line on dose increase
    • “Dose Escalation Schedule”dose increase · touches the card line on dose increase
    • “For adults, the recommended dosage of SAXENDA is 3 mg daily, lower dosages are for titration only.”dose schedule · touches the card line on dose schedule
    • “If more than 3 days have elapsed since the last SAXENDA dosage, reinitiate SAXENDA at 0.6 mg daily and follow the dosage escalation schedule in Table 1 , to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment.”dose increase · touches the card line on dose increase
    • “If patients do not tolerate an increased dose during dosage escalation, consider delaying dosage escalation for approximately one additional week.”dose increase · touches the card line on dose increase
    • “If pediatric patients do not tolerate an increased dose during dosage escalation, the dose may also be lowered to the previous level.”dose increase · touches the card line on dose increase
    • “No dosage adjustment is needed if changing the injection site and/or timing.”injection site
    • “SAXENDA is injected under the skin (subcutaneously) in your stomach area (abdomen), upper leg (thigh), or upper arm.”injection site
    • “The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 0.9 to 1.4 L/h with an elimination half-life of approximately 13 hours, making liraglutide suitable for once daily administration.”dose schedule · touches the card line on dose schedule
    • “Then follow the dosage escalation schedule in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.7 ), Adverse Reactions ( 6.1 )].”dose increase · touches the card line on dose increase